key: cord-0795843-v5aasksc authors: Acharya, Charlotte B; Schrom, John; Mitchell, Anthea M; Coil, David A; Marquez, Carina; Rojas, Susana; Wang, Chung Yu; Liu, Jamin; Pilarowski, Genay; Solis, Leslie; Georgian, Elizabeth; Belafksy, Sheri; Petersen, Maya; DeRisi, Joseph; Michelmore, Richard; Havlir, Diane title: Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected with the SARS-CoV-2 Delta Variant date: 2022-03-17 journal: Open Forum Infect Dis DOI: 10.1093/ofid/ofac135 sha: cd43225f3c5a9f7e9161d014f1472c43656cc1a5 doc_id: 795843 cord_uid: v5aasksc We found no significant difference in cycle threshold values between vaccinated and unvaccinated persons infected with SARS-CoV-2 Delta, overall or stratified by symptoms. Given the substantial proportion of asymptomatic vaccine breakthrough cases with high viral levels, interventions, including masking and testing, should be considered in settings with elevated COVID-19 transmission. A c c e p t e d M a n u s c r i p t 4 Vaccines reduce infection, severe disease, and death from SARS-CoV-2 (COVID-19) [1] . Yet breakthrough cases occur and this risk increases over time [2] . Reports predominantly from non-US settings suggest that viral loads from nasal swabs are similar among unvaccinated and vaccinated individuals; other reports suggest that virus levels are lower in unvaccinated persons [3] [4] [5] [6] . Here, we report on Ct-values among 869 fully Data were collected on individuals who voluntarily sought testing for SARS-CoV-2 from two demographically distinct populations in California during a two-month period (June 17-August 31, 2021), during which Delta was the predominant variant. HYT: As part of the response to COVID-19, UC Davis deployed an extensive free asymptomatic testing program that included the City of Davis and Yolo County (Healthy Yolo Together). Asymptomatic individuals over the age of two were eligible for testing. Asymptomatic cases were classified as individuals not reporting symptoms for at least 24 hours prior to testing. Under supervision, samples were collected by individuals transferring their saliva into barcoded tubes (COVID-19 Testing | Campus Ready). Smaller numbers of symptomatic individuals were processed using a different workflow and an antigen test; therefore, they were not included in this study. processed for qRT-PCR, genome recovery, and variant/lineage determination as previously described [8, 9] . Ct-values for the detection of N and E genes [9] were determined via the single threshold Cq-determination mode using Bio-Rad CFX Maestro v4.1 (Bio-Rad Inc). SARS-CoV-2 genomes were sequenced using the Illumina NovaSeq platform. Consensus genomes were generated via the COVID module of the IDseq pipeline (https://idseq.net) as described [9] . Ct-values were plotted, stratified by site; fully vs. not vaccinated; and symptom status. For persons in the UES with symptoms, Ct-values were plotted by time from symptom onset. Ct-values were compared by vaccine status, overall and stratified by symptom status, using a two-sided t-test. All participants provided informed consent for testing. Ct-values <20, of which 14 were asymptomatic at the time of testing. In our study, mean viral loads as measured by Ct-value were similar for large numbers of vaccinated and unvaccinated individuals infected with SARS-Cov-2 during the Delta variant surge, regardless of symptom status, at two distinct California testing sites. These results are in contrast to a large ongoing UK community cohort in which the median Ct-value was higher for vaccinated individuals (27.6) than for unvaccinated individuals (23.1) [3] , but are consistent with multiple other reports from the UK, Singapore, and the United States [4-6, 10, 11] . Our study contributes data from a large number of persons, including children, who were asymptomatic at the time of testing to inform this topic; most importantly, we demonstrate that 20% of positive, vaccinated individuals had low Ct-values (<20), a third of which were asymptomatic when tested. Given that low Ct-values are indicative of high levels of virus, culture positivity (including among vaccine breakthrough infections), and increased transmission [6, 12] , our detection of low Ct-values in asymptomatic, fully vaccinated individuals is consistent with the potential for, although does not prove, transmission from breakthrough infections prior to any emergence of symptoms. Two recent studies document that vaccinated individuals can transmit infection to vaccinated or unvaccinated persons even though they may show faster decay of viral loads and remain infectious for shorter periods of time than unvaccinated individuals [5, 12] . These viral dynamics may explain epidemiologic studies showing reduced transmission from vaccinated individuals [11, 13] . One important unanswered question is what proportion of infections are due to transmission from asymptomatic vaccine breakthroughs. A c c e p t e d M a n u s c r i p t 9 A limitation of our study is the lack of longitudinal data or information on the time of exposure for each person because these data were gathered as part of public health screening programs rather than in a clinical setting. Also, we did not collect data on immunodeficiency status. Vaccinated asymptomatic persons may have been tested either earlier or later in the course of infection than unvaccinated persons, complicating comparisons of Ct-values between these groups. It is also possible that some persons who were asymptomatic at time of testing later developed symptoms. However, our analysis shows that a vaccinated person may harbor high levels of virus during a period in which they are asymptomatic or presymptomatic. The data gathered in this study during the surge of the Delta variant strongly support the notion that neither vaccine status nor the presence or absence of symptoms should, by themselves, influence the recommendation and implementation of public health practices including mask wearing, testing, social distancing, and other measures designed to mitigate the spread of SARS-CoV-2 during periods of high transmission. National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study Despite Vaccination Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco Estimation of secondary household attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco Rapid deployment of SARS-CoV-2 testing: The CLIAHUB Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings-Barnsy Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19 Viral cultures for COVID-19 infectious potential assessment -a systematic review The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission A c c e p t e d M a n u s c r i p t 11